Asset Details
Do you wish to reserve the book?
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
Do you wish to request the book?
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
2015
Overview
There are limited treatment options for infection with the respiratory syncytial virus. In this human challenge model, a new oral nucleoside analogue, ALS-008176, showed modest antiviral activity.
Respiratory syncytial virus (RSV) infections are a cause of substantial morbidity and mortality in various patient populations worldwide, including children. Globally, RSV infections were estimated to cause 3.4 million hospitalizations and 66,000 to 199,000 deaths in 2005 in children younger than 5 years of age, primarily in the developing world.
1
In U.S. infants, RSV infection causes substantial outpatient disease
2
and is a common cause of hospitalization.
3
The risk of death from respiratory causes is nine times as high among U.S. infants with RSV infection as the risk among infants with influenza.
4
Immunocompromised patients and elderly patients, especially those with coexisting . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antiviral Agents - administration & dosage
/ Antiviral Agents - adverse effects
/ Antiviral Agents - pharmacokinetics
/ Deoxycytidine - administration & dosage
/ Deoxycytidine - adverse effects
/ Deoxycytidine - analogs & derivatives
/ Deoxycytidine - pharmacokinetics
/ Female
/ Humans
/ Male
/ Mucus
/ Respiratory Syncytial Virus Infections - drug therapy
/ Respiratory Syncytial Virus Infections - virology
/ Respiratory Syncytial Viruses - isolation & purification
/ Respiratory Syncytial Viruses - physiology
